Thank you too for pointing that out. I realized that I did not mention it in the article.

After looking into it again, the EMA has reported that "Time-to-onset ranged from 0 to 16 days," but this is based on blood clot incidents (including CVST) occurring as of 11 March 2021.

https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-chadox1-s-recombinant-covid_en.pdf

For CVST, specifically, DW news mentioned that "Those who have already received the AstraZeneca's vaccine should watch out for the following symptoms, according to Berlit: "People who have persistent and very severe headaches within the first 2-3 weeks after vaccination need to get further evaluation." Similarly, pinpoint-shaped hemorrhages in the skin along with headache may indicate CVST."

https://www.dw.com/en/astrazeneca-whats-the-deal-with-thrombosis/a-56901525